top of page

TARGETED THERAPY

Targeted therapy is a cancer treatment approach that uses drugs to selectively target and disrupt specific molecules or pathways that contribute to cancer cell growth and survival. Unlike conventional chemotherapy, which can cause harm to normal cells along with cancer cells, targeted therapies aim to minimize systemic toxicity by precisely targeting cancer cells and sparing normal cells.

Targeted therapies may act on various molecular targets, including cell surface receptors, intracellular signaling pathways, epigenetic regulators, or immune system components. The molecular target(s) for a given targeted therapy are typically selected based on the presence of specific molecular alterations in the tumor cells, such as gene mutations.

The most common classes of targeted therapy agents include monoclonal antibodies, small molecule inhibitors, and immunomodulatory agents. Monoclonal antibodies are engineered proteins that bind to specific cell surface receptors or other molecules on cancer cells, triggering immune-mediated cytotoxicity or blocking the downstream signaling events that promote tumor growth. 

Screenshot 2023-03-17 at 2.45.41 PM.png

Acalabrutinib belongs to the class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors. It is used for the treatment of certain types of cancer, specifically mantle cell lymphoma and chronic lymphocytic leukemia.

Acalabrutinib works by blocking the activity of the BTK enzyme, which is involved in the growth and survival of cancer cells. By inhibiting BTK, acalabrutinib can slow down or stop the growth and spread of cancer cells, potentially leading to remission or extended survival. Know more.

Screenshot 2023-10-26 at 12.00.12 PM.png

Cabozantinib is a Multiple Tyrosine Kinase Inhibitor . It is used in adults with Renal Cell Carcinoma(RCC) in combination with Nivolumab. Or as first line treatment in patients with Advance Renal Cell Carcinoma.  Cabozantinib works against tyrosine kinase enzymes that are responsible for cell proliferation, differentiation and migration. know more

Screenshot 2023-10-26 at 12.00.31 PM.png

Pazopanib is a Multiple tyrosine kinase inhibitor. It is used in adults in the treatment of advance Renal Cell Carcinoma (RCC), Adults with advanced soft tissue sarcoma(STS) that have received prior chemotherapy. Pazopanib works against  tyrosine kinase enzymes that are responsible for cell proliferation, differentiation and migration. know more

Screenshot 2023-10-26 at 12.00.22 PM.png
carfican carfilzomib

Carfilzomib is a medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It belongs to a class of drugs known as proteasome inhibitors. It works by inhibiting the proteasome. It is typically used in combination with other medications for the treatment of multiple myeloma. The specific treatment regimen, dosage, and duration of treatment are determined by a patient's healthcare provider based on their individual circumstances and the stage of their cancer. know more

bottom of page